Figure 2.

Network derived from Ingenuity Pathway Analysis software of children who achieved CRM status using MTX + Et (A) or MTX alone (B) compared with healthy controls. Network analysis is from PBMC (A) and granulocytes (B). Note the prominence of HNF4α as a hub in both networks. Genes shown in red show higher expression in patients compared with controls, and those shown in green show lower expression. CRM, clinical remission on medication; ET, etanercept; MTX, methotrexate; PBMC, peripheral blood mononuclear cells.

Jiang et al. Arthritis Research & Therapy 2013 15:R100   doi:10.1186/ar4280
Download authors' original image